Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 428062, 16 pages
http://dx.doi.org/10.5402/2012/428062
Review Article

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

Rita Nahta1,2,3,4

1Department of Pharmacology, School of Medicine Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA
2Department of Hematology and Medical Oncology, School of Medicine Emory University, Atlanta, GA 30322, USA
3Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
4Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA

Received 8 October 2012; Accepted 30 October 2012

Academic Editors: Y. Akiyama, S. Mohanam, and T. T. Trangas

Copyright © 2012 Rita Nahta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Rita Nahta, “Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer,” ISRN Oncology, vol. 2012, Article ID 428062, 16 pages, 2012. doi:10.5402/2012/428062